Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
AssigneeBoard of Regents, The University of Texas System
InventorsYoung-Jae NAM, Kunhua SONG, Eric N. OLSON
Life of this patent
Estimating the term…
Abstract
The present invention involves the use of transcription factors including Tbx5, Mef2C, Hand2, myocardin and Gata4 to reprogram cardiac fibroblasts into cardiomyocytes, both in vitro and in vivo. Such methods find particular use in the treatment of patients post-myocardial infarction to prevent or limit scarring and to promote myocardial repair.
Claims14
A method of reprogramming a cardiac fibroblast comprising contacting said cardiac fibroblast with Tbx5, Mef2C and Hand2.
2-40. (canceled)
A method preventing or delaying development of cardiac hypertrophy or heart failure in a subject having suffered a myocardial infarct (MI) comprising providing to said subject said Tbx5 and Mef2C or Tbx5 and Mef2C expression cassettes.
A method of reducing decrease in exercise tolerance, reducing hospitalization, improving quality of life, decreasing morbidity, and/or decreasing mortality of a subject having suffered a myocardial infarction comprising administering to said subject Tbx5 and Mef2C or Tbx5 and Mef2C expression cassettes.
52-59. (canceled)
Dependencies are inferred from the claim text.